title: Antiarrhythmic drug effects on QT interval dispersion in patients undergoing electropharmacologic testing for ventricular tachycardia and fibrillation.
abstract: The effects of antiarrhythmic drugs on QT interval dispersion as a predictor of antiarrhythmic drug therapy has not been rigorously assessed. This study was performed to determine whether the effects of antiarrhythmic drugs on QT interval dispersion predict antiarrhythmic drug response in patients undergoing electropharmacologic testing for ventricular tachycardiarrythmias. Precordial QT intervals and QT interval dispersions were measured at baseline and during steady-state antiarrhythmic drug therapy in 72 consecutive patients with documented coronary artery disease and remote myocardial infarction presenting with spontaneous sustained ventricular tachyarrhythmias who underwent electropharmacologic studies to assess arrhythmia suppression. QT interval dispersion was similar at baseline in drug responders (42 +/- 21 ms) and drug nonresponders (46 +/- 21 ms), whereas during antiarrhythmic therapy QT interval dispersion was shorter in drug responders (33 +/- 15 ms) than in drug nonresponders (55 +/- 29 ms, p <0.001). QT interval dispersion was shorter in 7 drug responders during their effective drug trials (27 +/- 14 ms) than during their ineffective drug trials (47 +/- 24 ms, n = 9, p <0.05). QT dispersion < or = 50 ms (p <0.002) and a patent infarct-related artery (p <0.003) were independent predictors of antiarrhythmic therapy. The positive and negative predictive value of QT interval dispersion during drug therapy to predict a successful drug response was 32% and 96%, respectively. QT interval dispersion predicted the outcome of electropharmacologic studies independent of infarct-related artery patency. QT interval dispersion >50 ms during drug therapy was associated with ineffective drug therapy.
authors.affiliation: Division of Cardiology, Foothills Medical Center and the University of Calgary, Alberta, Canada.
authors.forename: A M
authors.initials: AM
authors.lastname: Gillis
authors.forename: M
authors.initials: M
authors.lastname: Traboulsi
authors.forename: J T
authors.initials: JT
authors.lastname: Hii
authors.forename: D G
authors.initials: DG
authors.lastname: Wyse
authors.forename: H J
authors.initials: HJ
authors.lastname: Duff
authors.forename: M
authors.initials: M
authors.lastname: McDonald
authors.forename: L B
authors.initials: LB
authors.lastname: Mitchell
mesh_terms: D000368:Aged; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D005260:Female; D006329:Heart Conduction System / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000150:complications; D011237:Predictive Value of Tests; D017180:Tachycardia, Ventricular / Q000150:complications / Q000503:physiopathology*; D016896:Treatment Outcome; D014654:Vascular Patency; D014693:Ventricular Fibrillation / Q000150:complications / Q000503:physiopathology*
chemical_list: D000889:Anti-Arrhythmia Agents